Get to know our clinical trials
Phase I clinical trial of JNJ-75276617 in subjects with acute leukemia.
THE OBJECTIVE OF THIS STUDY IS TO DETERMINE IF A SAFE DOSE OF JNJ-75276617 CAN BE IDENTIFIED FOR THE TREATMENT OF PATIENTS WITH ACUTE LEUKEMIA, INCLUDING ACUTE MYELOID LEUKEMIA (AML) AND ACUTE LYMPHOBLASTIC LEUKEMIA (ALL). THERE ARE OTHER OBJECTIVES SUCH AS FINDING OUT WHETHER THE STUDY DRUG CAN BE BENEFICIAL IN THE TREATMENT OF ACUTE LEUKEMIA, HOW LONG IT STAYS AND ACTS IN THE BODY, AND HOW THE BODY RESPONDS TO THE DRUG.
Technical Summary
- FIRST-IN-HUMAN STUDY OF JNJ-75276617, A MENIN-KMT2A (MLL1) INHIBITOR, IN SUBJECTS WITH ACUTE LEUKEMIA.
- Code EudraCT: 2020-005967-30
- Protocol number: 75276617ALE1001
- Promoter: Janssen-Cilag
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.